Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial
Giulia Gianferrari,Riccardo Cuoghi Costantini,Valeria Crippa,Serena Carra,Valentina Bonetto,Orietta Pansarasa,Cristina Cereda,Elisabetta Zucchi,Ilaria Martinelli,Cecilia Simonini,Roberto Vicini,Nicola Fini,Francesca Trojsi,Carla Passaniti,Nicola Ticozzi,Alberto Doretti,Luca Diamanti,Giuseppe Fiamingo,Amelia Conte,Eleonora Dalla Bella,Eustachio D'Errico,Eveljn Scarian,Laura Pasetto,Francesco Antoniani,Veronica Galli,Elena Casarotto,Co-ALS Investigators Group,Roberto D'Amico,Angelo Poletti,Jessica Mandrioli,Francesca Prompicai,Silvia Parisi,Federico Banchelli,Laura Mediani,Vincenzo Silani,Mario Sabatelli,Giulia Bisogni,Giuseppe Lauria,Nilo Riva,Enrica Bersano,Isabella Laura Simone
DOI: https://doi.org/10.1093/braincomms/fcae304
2024-09-05
Abstract:In preclinical studies, the anti-inflammatory drug colchicine, which has never been tested in amyotrophic lateral sclerosis, enhanced the expression of autophagy factors and inhibited accumulation of transactive response DNA-binding protein 43 kDa, a known histopathological marker of amyotrophic lateral sclerosis. This multicentre, randomized, double-blind trial enrolled patients with probable or definite amyotrophic lateral sclerosis who experienced symptom onset within the past 18 months. Patients were randomly assigned in a 1:1:1 ratio to receive colchicine at a dose of 0.005 mg/kg/day, 0.01 mg/kg/day or placebo for a treatment period of 30 weeks. The number of positive responders, defined as patients with a decrease lesser than 4 points in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised total score during the 30-week treatment period, was the primary outcome. Disease progression, survival, safety and quality of life at the end of treatment were the secondary clinical outcomes. Secondary biological outcomes included changes from baseline to treatment end of stress granule and autophagy responses, transactive response DNA-binding protein 43 kDa, neurofilament accumulation and extracellular vesicle secretion, between the colchicine and placebo groups. Fifty-four patients were randomized to receive colchicine (n = 18 for each colchicine arm) or placebo (n = 18). The number of positive responders did not differ between the placebo and colchicine groups: 2 out of 18 patients (11.1%) in the placebo group, 5 out of 18 patients (27.8%) in the colchicine 0.005 mg/kg/day group (odds ratio = 3.1, 97.5% confidence interval 0.4-37.2, P = 0.22) and 1 out of 18 patients (5.6%) in the colchicine 0.01 mg/kg/day group (odds ratio = 0.5, 97.5% confidence interval 0.01-10.2, P = 0.55). During treatment, a slower Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised decline was detected in patients receiving colchicine 0.005 mg/kg/day (mean difference = 0.53, 97.5% confidence interval 0.07-0.99, P = 0.011). Eight patients experienced adverse events in placebo arm (44.4%), three in colchicine 0.005 mg/kg/day (16.7%) and seven in colchicine 0.01 mg/kg/day arm (35.9%). The differences in adverse events were not statistically significant. In conclusion, colchicine treatment was safe for amyotrophic lateral sclerosis patients. Further studies are required to better understand mechanisms of action and clinical effects of colchicine in this condition.